PRA Health Sciences (PRA) experts have significant experience providing end-to-end risk management services. Our integrated global teams identify innovative solutions to satisfy key regulatory requirements and provide effective strategies to ensure the benefit-risk profile of the product remains favorable for patients.
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…